Both UALCAN and HPA database revealed that SLC3A2 was significantly upregulated in BC patients at mRNA and protein level (Fig. 1F, G), thus playing a potential oncogenic role in BC progression. This evidence concerns the gene SLC3A2 and breast cancer.